



Notice Regarding Adjustment of 340B Prices for Select Products of Indivior Inc.

Indivior has recalculated its 340B ceiling prices for the period from Q4 2023 through Q1 2025 for the products listed below due to revisions made to its Medicaid pricing data. Indivior has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on OPA's public website to ensure transparency by providing access to information about Indivior's recalculation affecting certain 340B Covered Entities for the impacted product(s).

Indivior has determined the refund amount owed to each affected covered entity. Indivior will be working through Apexus, the HRSA 340B Prime Vendor, to issue refunds to each affected Covered Entity. Refunds will be issued either to a Covered Entity's validated wholesaler pharmacy account when one can be identified, or an ACH or check will be issued to Covered Entities whose wholesaler account cannot be identified.

NDC	Product Description	Time Period
12496012001	PERSERIS® (RISPERIDONE) INJ 120MG	Q4 23
12496010001	SUBLOCADE® 100MG/0.5ML	Q1 24 – Q1 25

If a Covered Entity believes they are due a refund and are not contacted by Apexus by December 1, 2025, you may contact Irene Coleman, Indivior Inc., Sr. Mgr. Government Pricing Irene.Coleman@indivior.com.